Bilateral Breast Carcinoma
Associated Genetic Biomarkers
NCI Definition: Carcinoma that affects both breasts in a simultaneous or non-simultaneous manner. 
There is 1 clinical trial for bilateral breast carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains bilateral breast carcinoma as an inclusion criterion, 1 is phase 2 (1 open).
ER, ERBB2, and HER2 are the most frequent gene inclusion criteria for bilateral breast carcinoma clinical trials .
Endocrine therapy and palbociclib are the most common interventions in bilateral breast carcinoma clinical trials.
Significant Genes in Bilateral Breast Carcinoma
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for bilateral breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and bilateral breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.